J&J to Acquire Halda Therapeutics in $3.05 B Deal to Bolster Oncology Pipeline

Johnson & Johnson (J&J) has announced that it will acquire Halda Therapeutics for approximately US$3.05 billion in cash. The acquisition brings Halda’s novel drug‐discovery platform and pipeline into J&J’s expansive oncology franchise. Halda specialises in a new class of small-molecule therapies called RIPTAC™ (Regulated Induced Proximity Targeting Chimeras) that selectively kill cancer cells by forging a harmful interaction between a tumour‐specific protein and an “essential” survival protein in the cancer cell.

Early clinical data for Halda’s lead candidate HLD-0915, targeting metastatic castration-resistant prostate cancer (mCRPC), showed encouraging signs of antitumour activity and a favourable therapeutic index. Through this deal, J&J aims to enhance its solid tumour portfolio, particularly in indications such as prostate cancer, breast cancer and lung cancer where resistance to standard therapy remains a major challenge. The companies expect the acquisition to be finalised in the coming months, subject to regulatory approvals. The move underscores J&J’s strategic push into high-growth oncology areas, in response to patent expirations on some of its legacy medicines.